NEWS | BEAM Alliance


XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

May 5, 2020 at 7:00 AM EDT

  • Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP

DUBLIN, Ireland, May 05, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases, an official journal of the Infectious Diseases Society of America (IDSA), has published results from a post-hoc analysis of clinical data from patients who initiated treatment in the hospital from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 clinical trials. The analyses indicate that lefamulin results in a rapid and similar time to clinical response, a proxy for hospital “discharge readiness,” compared to moxifloxacin. […]

“In the treatment of hospitalized patients with CABP, length of stay is the primary driver of the cost of care,” said Dr. Lodise. “Innovative antibiotics, such as lefamulin, that are safe and efficacious, and are shown to result in a rapid time to clinical response are critical to providing the most cost-effective and highest quality care to our patients.”

Full PR available here